查看文章

Oximes are cholinesterase reactivators used in organophosphorus poisoning. Clinical experience with pralidoxime (PRX) and other oximes is disappointing and their routine use has been questioned. In addition it is known that not all oximes are equally effective against all existing organophosphorus compounds. There is a demand for broad‐spectrum reactivators with a higher efficacy than PRX. Based on our previous in vitro work the protection conferred by the various new oximes against inhibition by paraoxon as quantified by the IC₅₀ shift (nm increase in the IC₅₀ of the inhibitor per µm oxime present) is: 0.3 (PRX), 0.4 (methoxime; MMC‐4), 1 (K‐33), 1.2 (BI‐6), 1.5 (K‐48) and 3.7 (K‐27).

The purpose of the study was to quantify in vivo the extent of oxime‐conferred protection, using paraoxon (POX) as a cholinesterase inhibitor and to test whether in vitro efficacy translates to protection from mortality.

There …